Skip to Content

Indication Assessment & Prioritization

How we help with Indication Assessment & Prioritization

We help many early-stage clients identify which development pathway is right for their business goals. Halloran helps to identify which assets and indications to prioritize and de-prioritize based on the client’s desired timeline, budget, early preclinical data, and clinical, regulatory, and commercial attributes. As part of this work, a Risk-Benefit Analysis for developing a drug or device in the indications under consideration can be provided as a guide to help mitigate potential pain points during the development.

RELATED INSIGHTS